Clinical studies that have used our HIFU therapy system have been reported in various published international and Chinese national level reports and peer-review journals. Some of them have been reported in multiple publications or presentations. These published studies have reported over 1,500 cases for the treatment of rectal tumors, bladder tumors, colon tumors, gastric tumors, ampullary tumors, liver tumors, pancreatic tumors, metastasis tumors of the abdominal lymph nodes, prostate tumors, adrenal tumors, kidney tumors, smooth muscle tumors, endometrial tumors, ovarian carcinoma, rear abdominal tumors, lymphoma tumors, cervical tumors, breast tumors, hepatocellular tumors, non-Hodgkin’s lymphoma, neurofibroma, osteolytic sarcoma and skin squamous tissue cancers. To date, our HIFU therapy system has been used in over 40,000 clinical cases.

These clinical studies have been conducted both by physicians affiliated with us as consultants and by other physicians in hospitals and universities in China, such as Peking University People’s Hospital, Fudan University Zhongshan Hospital, Beijing University Medical School, the Second-Affiliated Hospitals of Sun Yat-sen University, the First Hospital of Jilin University, Taian Central Hospitals, Qilu Hospital of Shandong University, the Central Railway Hospital of Liuzhou and the First Hospital of Jiangxi Medical University. Currently, our collaboration with the Chinese Ministry of Health ("MOH") in a large scale three-year study aims to demonstrate the clinical benefits of HIFU in combination with radiotherapy and chemotherapy.

In the United States, we plan to begin our clinical trial on a limited number of patients with advanced pancreatic cancer. These research initiatives conducted domestically and internationally are intended to study the effectiveness of our HIFU therapy system on various types of tumors.

In October 2007, we received official approval from the Korean Food and Drug Administration (the "KFDA") to market our HIFU Therapy System in Korea for the treatment of liver cancer, pancreatic cancer and uterine fibroids.

	Video: U.S. Preclinical Research Dr. Joo Ha Hwang, Dr. Stuart B. Mitchell University of Washington
	Video: Physician's Interview Dr. Xiaoye Hu Zhejiang University Second Affiliated Hospital
	Video: Physician's Interview Dr. Rongsheng Wang Nanjing Medical University First Affiliated Hospital
	Video: Physician's Interview Dr. Liulin Xiong Peking University People's Hospital
	Video: Physician's Interview Dr. Xin Ye Tai'an Central Hospital

For more information on HIFU clinical studies, please email: hifu_studies@chinameditech.com